Clinical Trial Update: A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BL-B01D1 to Topotecan in recurrent small cell lung cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• BL-B01D1
• Topotecan (topotecan)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING